Search results for "NON-ALCOHOLIC FATTY LIVER DISEASE"

showing 10 items of 266 documents

The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease

2016

Abstract We tested whether nonalcoholic fatty liver disease (NAFLD) and/or its histological severity are associated with vascular white matter lesions (WML) in patients with biopsy-proven NAFLD and in non-NAFLD controls. Data were recorded in 79 consecutive biopsy-proven NAFLD, and in 82 controls with normal ALT and no history of chronic liver diseases, without ultrasonographic evidence of steatosis and liver stiffness value  45 years (OR 3.09, 95% CI: 1.06–9.06, P = 0.03; and OR 11.1, 95% CI: 1.14–108.7, P = 0.03), and F2–F4 fibrosis (OR 3.36, 95% CI: 1.29–8.73, P = 0.01; and OR 5.34, 95% CI: 1.40–20.3, P = 0.01) were independently associated with WML (mostly of mild grade) by multivariate…

Liver CirrhosisMalePathologyBiopsySeverity of Illness IndexGastroenterology0302 clinical medicineRisk FactorsNon-alcoholic Fatty Liver DiseaseFibrosisNonalcoholic fatty liver diseaseUltrasonography4500Brain DiseasesSettore MED/12 - Gastroenterologiamedicine.diagnostic_testMedicine (all)Brain DiseaseGeneral MedicineMiddle AgedMagnetic Resonance ImagingWhite MatterFrontal Lobemedicine.anatomical_structureLiverFemale030211 gastroenterology & hepatologyNAFLD liver biopsy fibrosis white matter lesionsResearch ArticleHumanmedicine.medical_specialtyLiver CirrhosiObservational StudySettore MED/08 - Anatomia PatologicaDiagnosis DifferentialWhite matter03 medical and health sciencesInternal medicineBiopsySeverity of illnessmedicineHumansbusiness.industryRisk Factornutritional and metabolic diseasesmedicine.diseasedigestive system diseasesHyperintensityDifferential diagnosisSteatosisSettore MED/36 - Diagnostica Per Immagini E Radioterapiabusiness030217 neurology & neurosurgeryMedicine
researchProduct

Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non…

2017

Background Metabolic bone disorders frequently occur in patients with chronic liver disease; however, the association between liver fibrosis and bone mineral density in patients with non-alcoholic fatty liver disease (NAFLD) is unclear. Methods This is a cross-sectional analysis of 231 asymptomatic subjects (160 women, 61.6 years old) from a university hospital setting, between February 2012 and December 2014. Bone mineral density (BMD) was measured at the lumbar spine, femur neck, and total hip using dual-energy X-ray absorptiometry (DXA). Liver fibrosis and steatosis were assessed using transient elastography. Results Among a total of 231 individuals, 129 subjects (55.8%) had NAFLD. BMDs …

Liver CirrhosisMalePathologySteatosisBone densityOsteoporosislcsh:MedicineChronic liver diseasePathology and Laboratory MedicineGastroenterologyBiochemistryCytopathology0302 clinical medicineFibrosisBone DensityNon-alcoholic Fatty Liver DiseaseMedicine and Health SciencesFemurlcsh:ScienceMusculoskeletal SystemBone mineralMultidisciplinaryLumbar VertebraeLiver DiseasesFatty liverMiddle AgedLipidsCholesterolConnective TissueLiver FibrosisElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleAnatomyResearch Articlemusculoskeletal diseasesmedicine.medical_specialty030209 endocrinology & metabolismGastroenterology and HepatologyPelvis03 medical and health sciencesInternal medicinemedicineHumansBoneSkeletonAgedHipbusiness.industrylcsh:RBiology and Life Sciencesmedicine.diseaseFibrosisOsteopeniaFatty LiverBone Diseases MetabolicBiological TissueAnatomical Pathologylcsh:QbusinessTransient elastographyDevelopmental BiologyPLoS ONE
researchProduct

Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity

2019

Background & Aims: In patients with non-alcoholic fatty liver disease (NAFLD), liver biopsy is the gold standard to detect non-alcoholic steatohepatitis (NASH) and stage liver fibrosis. We aimed to identify differentially expressed mRNAs and non-coding RNAs in serum samples of biopsy-diagnosed mild and severe NAFLD patients with respect to controls and to each other. Methods: We first performed a whole transcriptome analysis through microarray (n = 12: four Control: CTRL; four mild NAFLD: NAS ≤ 4 F0; four severe NAFLD NAS ≥ 5 F3), followed by validation of selected transcripts through real-time PCRs in an independent internal cohort of 88 subjects (63 NAFLD, 25 CTRL) and in an external …

Liver CirrhosisMaleRNA UntranslatedMicroarrayBiopsyGastroenterologyliquid-biopsySeverity of Illness IndexTranscriptomeCohort Studies0302 clinical medicineFibrosisSettore BIO/13 - Biologia ApplicataNon-alcoholic Fatty Liver DiseaseMedicineSettore MED/12 - Gastroenterologiamedicine.diagnostic_testFatty liverArea under the curveNASHUntranslatedMiddle AgedLiver030220 oncology & carcinogenesisLiver biopsyDisease Progression030211 gastroenterology & hepatologyFemalefibrosiAdultmedicine.medical_specialty03 medical and health sciencesPredictive Value of TestsInternal medicineNAFLDliquid‐biopsyExtracellularHumansHepatologybusiness.industryGene Expression Profilingfibrosismedicine.diseaseRNAsMetabolic Liver DiseaseROC CurveRNASteatohepatitisbusinessBiomarkers
researchProduct

Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection

2012

Background: Limited data are available on hepatic steatosis (HS) in HIV patients who are not infected with hepatitis C virus (HCV). The aims of this study were to assess the prevalence of HS and its risk factors in HIV patients with and without HCV infection, and to evaluate whether HS correlates with advanced liver fibrosis and/or cardiovascular disease risk. Methods: Fifty-seven HIV mono-infected and 61 HIV/HCV co-infected patients were enrolled consecutively. All patients underwent liver ultrasound and transient elastography. The main parameters of liver function, HIV and HCV viral loads, CD4+ cell counts, and data on highly active antiretroviral therapy (HAART) were recorded. Cardiovasc…

Liver CirrhosisMaleSteatosisSettore MED/09 - Medicina InternaLipodystrophyAntiretroviral medicationHIV Infectionsmedicine.disease_causeGastroenterologyHIV/HCV co-infectedLiver diseaseRisk FactorsAntiretroviral Therapy Highly ActivePrevalenceMedicineProspective StudiesSteatosis HIV HIV/HCV co-infected Non-alcoholic fatty liver disease Liver disease Antiretroviral medication Metabolic syndrome LipodystrophyUltrasonographyeducation.field_of_studySettore MED/12 - GastroenterologiaFramingham Risk ScoreCoinfectionvirus diseasesGeneral MedicineMiddle AgedMetabolic syndromeHepatitis CInfectious DiseasesCardiovascular DiseasesFemaleLipodystrophyLiver diseaseViral loadMicrobiology (medical)Adultmedicine.medical_specialtySettore MED/17 - Malattie InfettiveAnti-HIV AgentsHepatitis C virusPopulationInternal medicineHumanseducationbusiness.industryHIVmedicine.diseaseFatty LiverImmunologyMultivariate AnalysisLiver functionbusinessTransient elastographyNon-alcoholic fatty liver disease
researchProduct

Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy

2020

Abstract Background and aims Nonalcoholic steatohepatitis (NASH) may progress to advanced liver disease (AdvLD). This study characterized comorbidities, healthcare resource utilization (HCRU) and associated costs among hospitalized patients with AdvLD due to NASH in Italy. Methods and results Adult nonalcoholic fatty liver disease (NAFLD)/NASH patients from 2011 to 2017 were identified from administrative databases of Italian local health units using ICD-9-CM codes. Development of compensated cirrhosis (CC), decompensated cirrhosis (DCC), hepatocellular carcinoma (HCC), or liver transplant (LT) was identified using first diagnosis date for each severity cohort (index-date). Patients progres…

Liver CirrhosisMaleTime FactorsCirrhosisDatabases FactualEndocrinology Diabetes and MetabolismMedicine (miscellaneous)ComorbidityHospital Cost030204 cardiovascular system & hematologyLiver diseasePatient Admission0302 clinical medicineRetrospective StudieNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseAmbulatory CarePrevalenceMedicineHospital Costseducation.field_of_studyDrug CostNutrition and DieteticsLiver NeoplasmsNASHMiddle AgedPrognosisItalyLiver NeoplasmHepatocellular carcinomaCohortDisease ProgressionHealth ResourcesFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularTime FactorAdolescentCostPrognosiLiver CirrhosiPopulation030209 endocrinology & metabolismPharmacyDrug CostsYoung Adult03 medical and health sciencesNAFLDInternal medicineHumanseducationAgedRetrospective StudiesHealth Resourcebusiness.industryRisk Factormedicine.diseaseComorbiditydigestive system diseasesLiver TransplantationHCRUbusinessAdministrative Claims HealthcareNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease

2014

BACKGROUND AND AIMS: Variant in glucokinase regulatory protein (GCKR), associated with lipid and glucose traits, has been suggested to affect fatty liver infiltration. We aimed to assess whether GCKR rs780094 C-->T SNP influences the expression of steatosis, lobular inflammation and fibrosis in NAFLD patients, after correction for PNPLA3 genotype. METHODS: In 366 consecutive NAFLD patients (197 from Sicily, and 169 from center/northern Italy), we assessed anthropometric, biochemical and metabolic features; liver biopsy was scored according to Kleiner. PNPLA3 rs738409 C>G and GCKR rs780094 C>T single nucleotide polymorphisms were also assessed. RESULTS: At multivariate logistic regression an…

Liver CirrhosisMalelcsh:MedicineNonalcoholic SteatohepatitisGene FrequencyFibrosisMedicineProspective Studieslcsh:ScienceSicilyliver fibrosisSettore MED/12 - GastroenterologiaMultidisciplinarymedicine.diagnostic_testGlucokinase regulatory proteinbiologyLiver DiseasesFatty liverMiddle Aged3. Good healthItalyLiver biopsyMedicineFemaleResearch ArticleAdultmedicine.medical_specialtyNAFLD GCKRGenotypeGENETICSgene polymorphismSingle-nucleotide polymorphismGastroenterology and HepatologyGLUCKINASESettore MED/08 - Anatomia PatologicaPolymorphism Single NucleotideNAFLDInternal medicineHumansGenetic Predisposition to DiseaseBiologySettore MED/42 - IGIENE GENERALE E APPLICATATriglyceridesPNPLA3Adaptor Proteins Signal TransducingEvolutionary BiologyPopulation Biologybusiness.industrylcsh:RSettore MED/09 - MEDICINA INTERNAComputational BiologyMembrane Proteinsnon-alcoholic fatty liver diseaseLipasePolymorphysmmedicine.diseaseLogistic ModelsEndocrinologyMetabolic DisordersMultivariate AnalysisGenetic Polymorphismbiology.proteinlcsh:QGlucokinase regulatory proteinGene polymorphismSteatosisSteatohepatitisbusinessPopulation GeneticsSteatohepatiti
researchProduct

Performance of morphologic criteria for the diagnosis of cirrhosis in patients with non-alcoholic steatohepatitis compared to other etiologies of chr…

2020

Purpose To compare the diagnostic performance of morphologic criteria for detection of cirrhosis in patients with alcoholic liver disease (ALD), hepatitis C (HCV), and non-alcoholic steatohepatitis (NASH). Methods One hundred patients (53 male) with different etiologies of chronic liver disease (NASH,n = 41; HCV,n = 39; and ALD,n = 20) and with different degrees of fibrosis on histopathologic examination (74 with cirrhosis) were retrospectively evaluated. Four readers (R1: fellowship-trained abdominal radiologist, R2: community attending radiologist, R3: senior radiology resident/research fellow, R4: junior radiology resident) analyzed the contrast-enhanced CTs for presence of commonly acce…

Liver CirrhosisMalemedicine.medical_specialtyAlcoholic liver diseaseCirrhosisUrologyChronic liver diseaseGastroenterology030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineNon-alcoholic fatty liver diseases (NAFLD)Non-alcoholic Fatty Liver DiseaseInternal medicineAscitesmedicineHumansRadiology Nuclear Medicine and imagingLiver Diseases AlcoholicComputed tomographyRetrospective StudiesRadiological and Ultrasound Technologybusiness.industryGastroenterologyHepatitis CHepatologymedicine.diseaseCirrhosis030220 oncology & carcinogenesisPortal hypertensionSteatohepatitismedicine.symptombusinessNon-alcoholic steatohepatiti
researchProduct

Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.

2018

Background & Aims: Baveno VI and expanded Baveno VI criteria can avoid the need for esophagogastroduodenoscopy (EGD) to screen for varices needing treatment (VNT) in a substantial proportion of compensated patients with viral and/or alcoholic cirrhosis. This multicenter, cross-sectional study aims to validate these criteria in patients with compensated cirrhosis due to non-alcoholic fatty liver disease (NAFLD), accounting for possible differences in liver stiffness measurement (LSM) values between M and XL probes. Methods: We assessed 790 patients with NAFLD-related compensated cirrhosis who had EGD within six months of a reliable LSM, measured by FibroScan® using M and/or XL probe. Baveno …

Liver CirrhosisMalemedicine.medical_specialtyAlcoholic liver diseaseCirrhosisVariceEsophageal and Gastric VaricesGastroenterology03 medical and health sciences0302 clinical medicineEsophageal varicesBaveno; Cirrhosis; NAFLD; Stiffness; Varices; Aged; Cross-Sectional Studies; Elasticity Imaging Techniques; Endoscopy Digestive System; Esophageal and Gastric Varices; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Platelet CountNon-alcoholic Fatty Liver DiseaseInternal medicineNAFLDmedicineHumansEndoscopy Digestive SystemBavenoScreening proceduresAgedCirrhosimedicine.diagnostic_testHepatologyEsophagogastroduodenoscopybusiness.industryPlatelet CountFatty liverHepatologyMiddle Agedmedicine.disease3. Good healthCross-Sectional Studies030220 oncology & carcinogenesisStiffneElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleVaricesbusinessJournal of hepatology
researchProduct

Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients with No…

2019

Some evidence suggests an interference of obesity and alanine aminotransferase (ALT) levels on the diagnostic accuracy for advanced fibrosis of noninvasive tools such as liver stiffness measurement (LSM) by FibroScan, Fibrosis-4 (FIB-4), and nonalcoholic fatty liver disease fibrosis score (NFS). We assessed whether the diagnostic accuracy of LSM, Fibrosis-4 (FIB-4), and NFS and strategies based on the combination of these tools is affected by obesity and/or ALT levels.METHODS:We analyzed data from 968 patients with a histological diagnosis of nonalcoholic fatty liver disease. FIB-4, NFS, and LSM by FibroScan were measured.RESULTS:LSM was better than both FIB-4 and NFS for staging F3-F4 fibr…

Liver CirrhosisMalemedicine.medical_specialtyBiopsySeverity of Illness IndexGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseasePredictive Value of TestsFibrosisInternal medicineSeverity of illnessBiopsyNonalcoholic fatty liver diseasemedicineHumansAspartate AminotransferasesObesityNASH FIBROSISHepatologymedicine.diagnostic_testbusiness.industryFatty liverGastroenterologyAlanine TransaminaseMiddle Agedmedicine.diseaseLiverROC Curve030220 oncology & carcinogenesisPredictive value of testsElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologySteatosisHepatic fibrosisbusinessBiomarkers
researchProduct

An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers

2018

Background & Aims Interventions aimed at lifestyle changes are pivotal for the treatment of non-alcoholic fatty liver disease (NAFLD), and web-based programs might help remove barriers in both patients and therapists. Methods In the period 2010–15, 716 consecutive NAFLD cases (mean age, 52; type 2 diabetes, 33%) were treated in our Department with structured programs. The usual protocol included motivational interviewing and a group-based intervention (GBI), chaired by physicians, dietitians and psychologists (five weekly meetings, n = 438). Individuals who could not attend GBI entered a web-based intervention (WBI, n = 278) derived from GBI, with interactive games, learning tests, motivati…

Liver CirrhosisMalemedicine.medical_specialtyMotivational interviewingPsychological interventionType 2 diabetesDisease03 medical and health sciences0302 clinical medicinePatient Education as TopicWeight lossNon-alcoholic Fatty Liver DiseaseInternal medicineWeight LossmedicineHumansNAFLD progression030212 general & internal medicineExerciseLife StyleAged2. Zero hungerInternetHepatologybusiness.industryPhysical activityFatty liverLiver enzymeAlanine TransaminaseHepatologyMiddle Agedmedicine.diseaseDiet; Liver enzymes; NAFLD progression; Physical activity; HepatologyTelemedicineLiver enzymes3. Good healthDietLogistic Models030211 gastroenterology & hepatologyFemalemedicine.symptombusinessBody mass indexBiomarkers
researchProduct